JP2009520021A5 - - Google Patents

Download PDF

Info

Publication number
JP2009520021A5
JP2009520021A5 JP2008547160A JP2008547160A JP2009520021A5 JP 2009520021 A5 JP2009520021 A5 JP 2009520021A5 JP 2008547160 A JP2008547160 A JP 2008547160A JP 2008547160 A JP2008547160 A JP 2008547160A JP 2009520021 A5 JP2009520021 A5 JP 2009520021A5
Authority
JP
Japan
Prior art keywords
amino
carboxamide
cinnoline
propyl
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008547160A
Other languages
English (en)
Japanese (ja)
Other versions
JP5148507B2 (ja
JP2009520021A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SE2006/001433 external-priority patent/WO2007073283A1/en
Publication of JP2009520021A publication Critical patent/JP2009520021A/ja
Publication of JP2009520021A5 publication Critical patent/JP2009520021A5/ja
Application granted granted Critical
Publication of JP5148507B2 publication Critical patent/JP5148507B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008547160A 2005-12-20 2006-12-18 Gabaa受容体調節物質としての置換シンノリン誘導体及びその合成法 Active JP5148507B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US75213705P 2005-12-20 2005-12-20
US60/752,137 2005-12-20
US82369306P 2006-08-28 2006-08-28
US60/823,693 2006-08-28
PCT/SE2006/001433 WO2007073283A1 (en) 2005-12-20 2006-12-18 Substituted cinnoline derivatives as gabaa-receptor modulators and method for their synthesis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012221312A Division JP5474153B2 (ja) 2005-12-20 2012-10-03 Gabaa受容体調節物質としての置換シンノリン誘導体

Publications (3)

Publication Number Publication Date
JP2009520021A JP2009520021A (ja) 2009-05-21
JP2009520021A5 true JP2009520021A5 (enExample) 2010-01-21
JP5148507B2 JP5148507B2 (ja) 2013-02-20

Family

ID=38188915

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008547160A Active JP5148507B2 (ja) 2005-12-20 2006-12-18 Gabaa受容体調節物質としての置換シンノリン誘導体及びその合成法
JP2012221312A Active JP5474153B2 (ja) 2005-12-20 2012-10-03 Gabaa受容体調節物質としての置換シンノリン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012221312A Active JP5474153B2 (ja) 2005-12-20 2012-10-03 Gabaa受容体調節物質としての置換シンノリン誘導体

Country Status (18)

Country Link
US (2) US7425556B2 (enExample)
EP (1) EP1966158B1 (enExample)
JP (2) JP5148507B2 (enExample)
KR (1) KR20080080206A (enExample)
CN (1) CN104592128A (enExample)
AR (1) AR056892A1 (enExample)
AU (1) AU2006327300A1 (enExample)
BR (1) BRPI0620126A2 (enExample)
CA (1) CA2634305A1 (enExample)
EC (1) ECSP088585A (enExample)
ES (1) ES2391472T3 (enExample)
IL (1) IL191762A0 (enExample)
NO (1) NO20083197L (enExample)
NZ (1) NZ569607A (enExample)
RU (1) RU2008122405A (enExample)
SA (1) SA06270474B1 (enExample)
UY (1) UY30032A1 (enExample)
WO (1) WO2007073283A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2391472T3 (es) * 2005-12-20 2012-11-27 Astrazeneca Ab Derivados de cinnolina sustituidos como moduladores del receptor de GABAA y método para su síntesis
US7465795B2 (en) * 2005-12-20 2008-12-16 Astrazeneca Ab Compounds and uses thereof
WO2008052139A2 (en) 2006-10-25 2008-05-02 Somaxon Pharmaceuticals, Inc. Ultra low dose doxepin and methods of using the same to treat sleep disorders
WO2008070795A2 (en) * 2006-12-06 2008-06-12 Somaxon Pharmaceuticals, Inc. Combination therapy using low-dose doxepin for the improvement of sleep
AR067028A1 (es) * 2007-06-19 2009-09-30 Astrazeneca Ab Compuestos y usos de los mismos 849
CA2725014C (en) 2008-05-30 2014-06-17 Amgen Inc. Inhibitors of pi3 kinase
AU2009307825A1 (en) * 2008-10-22 2010-04-29 Rick FRIEDMAN Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor
WO2010123440A1 (en) * 2009-04-21 2010-10-28 Astrazeneca Ab Pharmaceutical composition comprising 4-amino-8-(2-fluoro-6-methoxy-phenyl)-n- propylcinnoline-3-carboxamide hydrogen sulphate and rate-controlling polymer
WO2010123443A1 (en) * 2009-04-21 2010-10-28 Astrazeneca Ab Pharmaceutical composition comprising 4-amino-8-(2-fluoro-6-methoxy-phenyl)-n- propylcinnoline-3-carboxamide hydrogen sulphate.
WO2010123441A1 (en) * 2009-04-21 2010-10-28 Astrazeneca Ab Crystalline form of 4-amino-8-(2-fluoro-6-methoxy-phenyl)-n-propylcinnoline-3- carboxamide hydrogen sulphate, for treatment of anxiety disorders
WO2011021979A1 (en) * 2009-08-18 2011-02-24 Astrazeneca Ab Cinnoline compounds, their preparation, and their use
MA34591B1 (fr) 2010-10-06 2013-10-02 Glaxosmithkline Llc Dérivés de benzimidazole utilisés comme inhibiteurs de pi3 kinase
WO2012162254A1 (en) * 2011-05-23 2012-11-29 Elan Pharmaceuticals, Inc. Inhibitors of lrrk2 kinase activity
WO2013148603A1 (en) * 2012-03-27 2013-10-03 Takeda Pharmaceutical Company Limited Cinnoline derivatives as as btk inhibitors
JP6152260B2 (ja) 2012-11-01 2017-06-21 昭和電工パッケージング株式会社 電池用外装材及び電池
US9844551B2 (en) * 2015-01-14 2017-12-19 Children's Hospital Medical Center Compositions and methods for treatment of fragile X syndrome
CA3068350A1 (en) 2017-06-30 2019-01-03 Bayer Animal Health Gmbh New azaquinoline derivatives
US11911364B2 (en) 2018-09-25 2024-02-27 Pepticom Ltd. Positive allosteric modulators of GABAA receptor
WO2021204930A1 (en) 2020-04-09 2021-10-14 Bayer Animal Health Gmbh Substituted condensed azines as anthelmintic compounds
GB202016245D0 (en) 2020-10-13 2020-11-25 Univ College Cardiff Consultants Ltd Compounds
AU2024262043A1 (en) * 2023-04-24 2025-11-20 Shanghai SIMR Biotechnology Co., Ltd Imidazopyridine or imidazopyrazine compound, preparation method therefor, and pharmaceutical composition and use thereof
CN119638634A (zh) * 2023-09-18 2025-03-18 上海赛默罗生物科技有限公司 噌啉-2-氧化物类化合物及其制备方法和用途

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4230713A (en) 1979-01-19 1980-10-28 Ici Americas Inc. Heterocyclic tetrahydro-1-alkyl-4-oxo-1H-imidazol-2-ylidene urea and phenyl esters of tetrahydro-1-alkyl-4-oxo-1H-imidazol-2-ylidene carbamic acid compounds
GB8310266D0 (en) 1982-05-12 1983-05-18 Ici America Inc Pyrazolopyridine compounds
US4552883A (en) 1982-06-15 1985-11-12 Ici Americas Inc. Pyrazolo[3,4-b]pyridine carboxylic acid esters and their pharmaceutical use
US4563525A (en) 1983-05-31 1986-01-07 Ici Americas Inc. Process for preparing pyrazolopyridine compounds
GB8329531D0 (en) 1983-11-04 1983-12-07 Ici America Inc Pyrazolopyridine cycloalkanones
GB8421116D0 (en) 1984-08-20 1984-09-26 Ici America Inc Alkynyl derivatives
GB8425104D0 (en) 1984-10-04 1984-11-07 Ici America Inc Amide derivatives
GB8513639D0 (en) * 1985-05-30 1985-07-03 Ici America Inc Cinnoline compounds
GB8610980D0 (en) 1986-05-06 1986-06-11 Ici America Inc Heterocyclic fused tricyclic compounds
DD249011A5 (de) 1986-06-20 1987-08-26 Ici Americas Inc,Us Verfahren zur herstellung von cinnolin-verbindungen
US4925844A (en) 1988-02-09 1990-05-15 Ici Americas Inc. Antagonizing the pharmacological effects of a benzodiazepine receptor agonist
ATE79540T1 (de) * 1988-02-09 1992-09-15 Ici America Inc Pharmazeutische zusammensetzung.
US5240934A (en) 1990-10-19 1993-08-31 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
US5190951A (en) 1990-10-19 1993-03-02 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
WO1992016497A1 (fr) 1991-03-22 1992-10-01 Japan Tobacco Inc. Derive d'acide amine ayant une activite inhibant la renine
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
ES2108120T3 (es) 1991-05-10 1997-12-16 Rhone Poulenc Rorer Int Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf.
US5750088A (en) 1993-03-30 1998-05-12 The Dupont Merck Pharmaceutical Company Stable hydrazones linked to a peptide moiety as reagents for the preparation of radiopharmaceuticals
JP3989955B2 (ja) 1995-07-25 2007-10-10 アルヒミカ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング クロス・カップリング反応を実施する方法
DE19620023C2 (de) 1996-05-17 2001-03-08 Celanese Chem Europe Gmbh Verfahren zur Herstellung von Phosphinat- oder Phosphonatgruppen enthaltenden tertiären Phosphanen und neue Phosphinatgruppen enthaltende tertiäre Phosphane
GB9607219D0 (en) 1996-04-04 1996-06-12 Smithkline Beecham Plc Novel compounds
JP2002506073A (ja) 1998-03-12 2002-02-26 ノボ ノルディスク アクティーゼルスカブ プロテイン・チロシン・ホスファターゼ(PTPases)のモジュレーター
WO1999047474A1 (en) 1998-03-18 1999-09-23 Ciba Specialty Chemicals Holding Inc. Coupling reactions with palladium catalysts
US6362216B1 (en) 1998-10-27 2002-03-26 Array Biopharma Inc. Compounds which inhibit tryptase activity
DE19916222A1 (de) 1999-04-10 2000-10-19 Aventis Res & Tech Gmbh & Co Verfahren zur Herstellung von Biarylen
GB9919957D0 (en) 1999-08-23 1999-10-27 Merck Sharp & Dohme Therapeutic agents
GB9921150D0 (en) 1999-09-07 1999-11-10 Merck Sharp & Dohme Therapeutic agents
GB9921351D0 (en) 1999-09-09 1999-11-10 Merck Sharp & Dohme Therapeutic agents
GB9927687D0 (en) 1999-11-23 2000-01-19 Merck Sharp & Dohme Therapeutic agents
FR2801584B1 (fr) 1999-11-26 2003-05-30 Rhodia Chimie Sa Procede de preparation d'un compose polyaromatique
GB9929685D0 (en) 1999-12-15 2000-02-09 Merck Sharp & Dohme Therapeutic agents
GB9929687D0 (en) 1999-12-15 2000-02-09 Merck Sharp & Dohme Therapeutic agents
CN1398258A (zh) 2000-03-21 2003-02-19 法玛西雅厄普约翰美国公司 用作抗病毒剂的4-羟基噌啉-3-甲酰胺化合物
MY145722A (en) * 2000-04-27 2012-03-30 Abbott Lab Diazabicyclic central nervous system active agents
EA200201233A1 (ru) 2000-05-19 2003-04-24 Эли Лилли Энд Компани Способ получения бифенильных соединений
US6984756B2 (en) 2000-05-19 2006-01-10 Eli Lilly And Company Process for preparing biphenyl compounds
US6642229B2 (en) 2000-05-24 2003-11-04 Merck Sharp & Dohme Ltd. 3-Phenyl-imidazo-pyrimidine derivatives as ligands for GABA receptors
AUPQ841300A0 (en) 2000-06-27 2000-07-20 Fujisawa Pharmaceutical Co., Ltd. New aminoalcohol derivatives
GB0018473D0 (en) 2000-07-27 2000-09-13 Merck Sharp & Dohme Therapeutic agents
WO2002063766A2 (en) 2000-11-01 2002-08-15 Primarion, Inc. Method and apparatus for detecting valid signal information
ATE310740T1 (de) 2000-11-10 2005-12-15 Merck Sharp & Dohme Imidazotriazin-derivate als liganden für gaba- rezeptoren
GB0027561D0 (en) 2000-11-10 2000-12-27 Merck Sharp & Dohme Therapeutic agents
GB0111191D0 (en) 2001-05-08 2001-06-27 Merck Sharp & Dohme Therapeutic agents
WO2003003009A1 (en) 2001-06-29 2003-01-09 7Tm Pharma A/S Use of metal-ion chelates in validating biological molecules as drug targets in test animal models
GB0117060D0 (en) 2001-07-12 2001-09-05 Merck Sharp & Dohme Therapeutic agents
GB0119803D0 (en) 2001-08-14 2001-10-10 Merck Sharp & Dohme Therapeutic agents
GB0119828D0 (en) 2001-08-14 2001-10-10 Merck Sharp & Dohme Therapeutic agents
GB0120345D0 (en) 2001-08-21 2001-10-17 Merck Sharp & Dohme Therapeutic agents
AUPR738301A0 (en) 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
GB0122696D0 (en) 2001-09-20 2001-11-14 Merck Sharp & Dohme Therapeutic agents
EP1513522A2 (en) 2002-01-18 2005-03-16 Sri International Methods of treating conditions associated with an edg receptor
US20050113283A1 (en) 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
GB0208394D0 (en) 2002-04-11 2002-05-22 Merck Sharp & Dohme Therapeutic agents
PL189894B1 (pl) * 2002-04-15 2005-10-31 Univ Medyczny W Lodzi Sposób wytwarzania 6,7,8-podstawionych kwasów 4-hydroksycynnolino-3-karboksylowych
GB0210127D0 (en) 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0210124D0 (en) 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0212049D0 (en) 2002-05-24 2002-07-03 Merck Sharp & Dohme Therapeutic agents
GB0212048D0 (en) 2002-05-24 2002-07-03 Merck Sharp & Dohme Therapeutic agents
JP2006502991A (ja) 2002-07-17 2006-01-26 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリックスメタロプロテイナーゼ−13のアロステリックアルキン阻害剤とセレコキシブまたはバルデコキシブではないシクロオキシゲナーゼ−2の選択的阻害剤との組合せ物
GB0218876D0 (en) 2002-08-13 2002-09-25 Merck Sharp & Dohme Therapeutic agents
AU2003246979B8 (en) 2002-08-13 2009-08-06 Merck Sharp & Dohme Limited Phenylpyridazine derivatives as ligands for GABA receptors
SE0202461D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
EP1558585B1 (en) 2002-10-04 2013-09-25 Prana Biotechnology Limited Neurologically-active compounds
US20040102360A1 (en) 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
AU2003270701B2 (en) 2002-10-31 2009-11-12 Amgen Inc. Antiinflammation agents
GB0225501D0 (en) 2002-11-01 2002-12-11 Merck Sharp & Dohme Therapeutic agents
GB0226462D0 (en) 2002-11-13 2002-12-18 Merck Sharp & Dohme Therapeutic agents
US20040167165A1 (en) 2003-01-16 2004-08-26 Geetha Shankar Methods of treating conditions associated with an Edg-7 receptor
GB0301350D0 (en) 2003-01-21 2003-02-19 Merck Sharp & Dohme Therapeutic agents
WO2004076452A1 (en) 2003-02-26 2004-09-10 Merck Sharp & Dohme Limited 5,8-DIFLUOROIMIDAZO[1,2-a]PYRIDINES AS GABA-A α2/α3 LIGANDS FOR TREATING ANXIETY AND/OR DEPRESSION
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
WO2005024416A1 (en) 2003-09-05 2005-03-17 Binghe Wang Water soluble boronic acid fluorescent reporter compounds and methods of use thereof
US7790734B2 (en) 2003-09-08 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
AU2004293436B2 (en) 2003-11-19 2010-12-09 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
WO2006124996A2 (en) * 2005-05-17 2006-11-23 Supergen, Inc. Inhibitors of polo-like kinase-1
US7465795B2 (en) * 2005-12-20 2008-12-16 Astrazeneca Ab Compounds and uses thereof
ES2391472T3 (es) * 2005-12-20 2012-11-27 Astrazeneca Ab Derivados de cinnolina sustituidos como moduladores del receptor de GABAA y método para su síntesis
AR067028A1 (es) * 2007-06-19 2009-09-30 Astrazeneca Ab Compuestos y usos de los mismos 849

Similar Documents

Publication Publication Date Title
JP2009520021A5 (enExample)
RU2008122405A (ru) Замещенные производные циннолина в качестве модуляторов гамма-рецепторов и способ их синтеза
RU2497822C2 (ru) Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний
JP2006509748A5 (enExample)
JP2017537948A5 (enExample)
JP2014526549A5 (enExample)
JP2009526072A5 (enExample)
JP2019505541A5 (enExample)
JP2007519754A5 (enExample)
RU2017121044A (ru) Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы
JP2008542279A5 (enExample)
JP2005526723A5 (enExample)
JP2009524589A5 (ja) 置換されたイソキノリン−1,3(2h,4h)−ジオン、1−チオキソ−1,4−ジヒドロ−2h−イソキノリン−3−オン、および1,4−ジヒドロ−3(2h)−イソキノロン、ならびにキナーゼインヒビターとしてのそれらの使用
JP2017530199A5 (enExample)
JP2009541311A5 (enExample)
HRP20160359T1 (hr) Derivati kinazolindiona, njihovo dobivanje i njihove terapijske primjene
JP2013532727A5 (enExample)
JP2013505949A5 (enExample)
JP2012519693A5 (enExample)
JP2017525757A5 (enExample)
HRP20130865T1 (hr) Derivati pirazol piridina kao inhibitori nadph oksidaze
JP2013517283A5 (enExample)
JP2005508313A5 (enExample)
JP2007510689A5 (enExample)
JP2009520685A5 (enExample)